Nature’s Toolbox, Inc. (NTx), a Rio Rancho, NM-baseed life sciences company building next generation platforms to manufacture RNA and protein, raised $47.5M in Series B financing.
The round was led by RA Capital Management and MP Peter Kolchinsky, Ph.D. joined NTx’ Board of Directors.
The company intends to use the funds to advance its biomanufacturing platforms, NTxscribe® and NTxpress®.
Led by Jamie Coffin, Ph.D., CEO, NTx is developing innovative systems like NTxpress® and NTxscribe® to enable manufacturing of mRNA vaccines and protein therapeutics in an eco-friendly and sustainable way. The NTxscribe platform is a cell-free, true continuous flow manufacturing system that delivers scalable RNA materials in a small footprint. NTxscribe is currently being deployed in BioPharma research and development to help expedite mRNA therapeutic development. It is also the technology being evaluated in the first Vaccines-on-Demand contract awarded by BARDA DRIVe for pandemic preparedness. NTxpress is a fully recombinant cell-free expression system that produces proteins while minimizing unwanted cellular metabolism.
FinSMEs
17/11/2023